McNeill Jonathan
SEC CIK 1824673 · EDGAR
BoughtSold
Most active insiders at CBIO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Harwin Peter Evan | Dir, 10% | $18.24M | — |
| 2 | Fairmount Funds Management LLC | Dir, 10% | $12.38M | — |
| 3 | Brumm Joshua T | CEO, Dir | — | $920.8K |
| 4 | McNeill Jonathan | Pres, COO | — | $446.9K |
| 5 | Pinkas Jan | CSO | — | $34.9K |
| 6 | Im Ellie Eunkyung | Chief Medical Off | — | $33.1K |
| 7 | Bispham Barbara Harlin | See Remarks | — | $33.0K |
| 8 | Scalzo Richard William | CFO | — | $30.2K |
| 9 | Lynch Ryan | See Remarks | — | $12.7K |
| 10 | Doughty Christopher Grant | Chief Business Off | — | — |
Transactions 32
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-18 16:01 | 2026-09-16+ | CBIO | CRESCENT BIOPHARMA, INC. | McNeill Jonathan | Pres, COO | S - Sale | $16.90 | -4,570 | 134.6K | -3% | -$77.2K |
| T | 2026-06-23 16:02 | 2026-06-22 | CBIO | CRESCENT BIOPHARMA, INC. | McNeill Jonathan | Pres, COO | S - Sale | $17.99 | -20.5K | 139.2K | -13% | -$369.7K |
| DM | 2025-12-17 | 2025-12-15 | CBIO | CRESCENT BIOPHARMA, INC. | McNeill Jonathan | Pres, COO | A - Grant | — | +25.5K | 159.7K | +19% | — |
| MT | 2024-08-20 | 2024-08-19 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale | $45.12 | -2,705 | 132.4K | -2% | -$122.1K |
| 2024-06-11 | 2024-06-11 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale | $31.34 | -1,823 | 134.8K | -1% | -$57.1K | |
| MT | 2024-05-17 | 2024-05-16 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale | $28.27 | -2,774 | 137.1K | -2% | -$78.4K |
| DMT | 2024-03-13 | 2024-03-08+ | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale+OE | $26.11 | -109.6K | 141.9K | -44% | -$2.86M |
| DMT | 2024-03-13 | 2024-03-08+ | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | M - OptEx | $5.54 | +107.8K | 227.3K | +90% | +$597.4K |
| T | 2024-03-11 | 2024-03-07 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale | $25.85 | -2,434 | 141.2K | -2% | -$62.9K |
| DMT | 2024-03-01 | 2024-02-29+ | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | M - OptEx | $0.73 | +28.5K | 167.9K | +20% | +$20.8K |
| DMT | 2024-03-01 | 2024-02-29+ | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale+OE | $28.46 | -28.5K | 143.6K | -17% | -$811.9K |
| DT | 2024-01-26 | 2024-01-26 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | M - OptEx | $0.73 | +20.0K | 163.6K | +14% | +$14.6K |
| DMT | 2024-01-26 | 2024-01-26 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale+OE | $24.53 | -20.0K | 143.8K | -12% | -$490.5K |
| DMT | 2024-01-04 | 2024-01-03+ | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | M - OptEx | $0.73 | +20.0K | 161.6K | +14% | +$14.6K |
| DMT | 2024-01-04 | 2024-01-02+ | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale+OE | $16.59 | -31.9K | 143.6K | -18% | -$529.2K |
| 2023-12-12 | 2023-12-11 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale | $10.72 | -1,245 | 155.5K | -0.8% | -$13.3K | |
| D | 2023-11-16 | 2023-11-15 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | A - Grant | $0.00 | +96.2K | 156.8K | +159% | $0 |
| 2023-09-20 | 2023-09-18 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale | $9.41 | -1,261 | 60.6K | -2% | -$11.9K | |
| 2023-09-13 | 2023-09-12 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Off | S - Sale | $10.41 | -1,266 | 61.9K | -2% | -$13.2K | |
| M | 2023-06-14 | 2023-06-12+ | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | S - Sale | $12.68 | -2,259 | 64.4K | -3% | -$28.6K |
| M | 2023-03-15 | 2023-03-13+ | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | S - Sale | $13.18 | -2,209 | 65.4K | -3% | -$29.1K |
| D | 2023-01-23 | 2023-01-18 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | M - OptEx | $0.73 | +10.0K | 77.6K | +15% | +$7,300 |
| D | 2023-01-23 | 2023-01-18 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | S - Sale+OE | $14.03 | -10.0K | 67.6K | -13% | -$140.3K |
| 2023-01-11 | 2023-01-09 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | S - Sale | $11.57 | -30.1K | 67.6K | -31% | -$348.8K | |
| D | 2022-12-13 | 2022-12-09 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | A - Grant | $0.00 | +40.0K | 98.2K | +69% | $0 |
| D | 2022-12-13 | 2022-12-12 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | S - Sale | $10.87 | -472 | 97.8K | -0.5% | -$5,131 |
| 2022-09-21 | 2022-09-20 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | D - Sale to Iss | $13.70 | -1,246 | 58.2K | -2% | -$17.1K | |
| 2022-09-15 | 2022-09-15 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | D - Sale to Iss | $14.05 | -494 | 59.5K | -0.8% | -$6,941 | |
| 2022-06-15 | 2022-06-14 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | D - Sale to Iss | $4.95 | -504 | 60.0K | -0.8% | -$2,495 | |
| 2022-03-14 | 2022-03-11 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | S - Sale | $8.73 | -481 | 60.5K | -0.8% | -$4,199 | |
| D | 2021-12-14 | 2021-12-10 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | A - Grant | $0.00 | +25.3K | 60.9K | +71% | $0 |
| M | 2021-09-22 | 2021-09-20+ | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | S - Sale | $15.90 | -1,274 | 36.4K | -3% | -$20.3K |
Purchase Sale Sale after option exercise All abbreviations